flecainide has been researched along with Disease Models, Animal in 58 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Inhaled flecainide significantly alters atrial electrical properties with the potential to terminate atrial fibrillation (AF) efficiently by optimizing dose and drug formulation." | 7.96 | Multimodal mechanisms and enhanced efficiency of atrial fibrillation cardioversion by pulmonary delivery of a novel flecainide formulation. ( Araujo Silva, B; Belardinelli, L; Bortolotto, AL; Hurrey, M; Madhavapeddi, P; Medeiros, SA; Pedreira, GC; Schuler, C; Tessarolo Silva, F; Verrier, RL, 2020) |
| "We investigated whether rapid administration of a low dose of flecainide, either intratracheally or intravenously (IV), could accelerate conversion of atrial fibrillation (AF) while reducing adverse ventricular effects." | 7.91 | Optimizing flecainide plasma concentration profile for atrial fibrillation conversion while minimizing adverse ventricular effects by rapid, low-dose intratracheal or intravenous administration. ( Belardinelli, L; Bortolotto, AL; de Antonio, VZ; Marum, AA; Silva, AC; Silva, BA; Verrier, RL, 2019) |
| "Blockade of inward-rectifier K+ channels by chloroquine terminates reentry in cholinergic atrial fibrillation (AF)." | 7.78 | Chloroquine terminates stretch-induced atrial fibrillation more effectively than flecainide in the sheep heart. ( Bandaru, K; Berenfeld, O; Calvo, CJ; Ennis, SR; Filgueiras-Rama, D; Jalife, J; Kalifa, J; Martins, RP; Mironov, S; Noujaim, SF; Yamazaki, M, 2012) |
| "As a molecular model of the effect of ischemia on drug block of the transient outward potassium current, the effect of acidosis on the blocking properties of flecainide and quinidine on Kv4." | 7.72 | Extracellular acidosis modulates drug block of Kv4.3 currents by flecainide and quinidine. ( Bauskin, A; Breit, S; Bursill, J; Campbell, T; Singarayar, S; Vandenberg, J; Wu, W; Wyse, K, 2003) |
| "Electrophysiologic and hemodynamic effects of SD-3212, a new antiarrhythmic drug, were examined and compared with those of flecainide, a class Ic antiarrhythmic drug, in a canine myocardial infarction model." | 7.69 | Comparison of electrophysiologic and hemodynamic effects of SD-3212, a new antiarrhythmic drug, and flecainide in a canine myocardial infarction model. ( Araki, S; Hashimoto, H; Ishii, M; Nagashima, S; Nakashima, M; Uematsu, T; Umemura, K, 1994) |
| "Antiarrhythmic effects of bisaramil were examined by using new in vivo triggered arrhythmia models, and they were compared with those of other antiarrhythmic drugs." | 7.69 | Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog. ( Haruno, A; Hashimoto, K, 1995) |
| "Effects of flecainide, a class I antiarrhythmic drug, on ventricular arrhythmias, ventricular abnormal automaticity and ventricular activation were examined in a canine model of myocardial infarction, and compared with those of lidocaine." | 7.68 | Effects of flecainide on ventricular arrhythmias, abnormal automaticity and activation in a canine model of myocardial infarction. ( Hashimoto, H; Katoh, H; Nakashima, M, 1992) |
| "The properties of a class 1c antiarrhythmic drug, flecainide, were examined using 3 canine ventricular arrhythmia models: (1) digitalis-, (2) adrenaline- and (3) two-stage coronary ligation-induced arrhythmias." | 7.67 | Antiarrhythmic effects of the class 1c antiarrhythmic drug, flecainide, on canine ventricular arrhythmia models. ( Akiyama, K; Hashimoto, K, 1989) |
| "Flecainide has been reported to be effective in suppressing chronic ventricular arrhythmias in clinical studies, but the electrophysiological mechanisms of its action are not understood." | 7.67 | Electrophysiological effects of flecainide in a canine 7 day old myocardial infarction model. ( Hosokawa, M; Miyazaki, T; Nakamura, Y; Ogawa, S; Sakai, T; Sakurai, K, 1989) |
| "Flecainide was also potent in suppressing microglial activation in experimental autoimmune encephalomyelitis." | 5.39 | Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. ( Bechtold, D; Chauhdry, S; Hassoon, P; Lee, W; Malpass, K; Morsali, D; Palchaudhuri, U; Piers, T; Pocock, J; Roach, A; Smith, KJ; Snell, DM, 2013) |
| " Seven additional postinfarction dogs with noninducible tachycardia during pretreatment programmed stimulation, and thereby considered to be at "low risk" for the development of ischemic ventricular fibrillation, were also given flecainide in an intravenous loading and maintenance dosing regimen." | 5.27 | Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death. ( DiCarlo, L; Kou, WH; Lucchesi, BR; Lynch, JJ; Montgomery, DG; Nelson, SD, 1987) |
| "Inhaled flecainide significantly alters atrial electrical properties with the potential to terminate atrial fibrillation (AF) efficiently by optimizing dose and drug formulation." | 3.96 | Multimodal mechanisms and enhanced efficiency of atrial fibrillation cardioversion by pulmonary delivery of a novel flecainide formulation. ( Araujo Silva, B; Belardinelli, L; Bortolotto, AL; Hurrey, M; Madhavapeddi, P; Medeiros, SA; Pedreira, GC; Schuler, C; Tessarolo Silva, F; Verrier, RL, 2020) |
| "We investigated whether rapid administration of a low dose of flecainide, either intratracheally or intravenously (IV), could accelerate conversion of atrial fibrillation (AF) while reducing adverse ventricular effects." | 3.91 | Optimizing flecainide plasma concentration profile for atrial fibrillation conversion while minimizing adverse ventricular effects by rapid, low-dose intratracheal or intravenous administration. ( Belardinelli, L; Bortolotto, AL; de Antonio, VZ; Marum, AA; Silva, AC; Silva, BA; Verrier, RL, 2019) |
| "Modafinil is a non-amphetaminic wake-promoting compound used as therapy against sleepiness and narcolepsy." | 3.83 | Impact of Astroglial Connexins on Modafinil Pharmacological Properties. ( Charvériat, M; Chauveau, F; Dauvilliers, Y; Duchêne, A; Giaume, C; Jeanson, T; Lagarde, D; Lin, JS; Liu, X; Mouthon, F; Perier, M; Picoli, C; Piérard, C; Thomasson, J; Zhao, Y, 2016) |
| "Flecainide-induced arrhythmia may be partly accounted for by attenuated adaptation of ventricular repolarization to sudden changes in cardiac cycle length provoked by transient tachycardia or ectopic beats." | 3.83 | Flecainide attenuates rate adaptation of ventricular repolarization in guinea-pig heart. ( Osadchii, OE, 2016) |
| "Blockade of inward-rectifier K+ channels by chloroquine terminates reentry in cholinergic atrial fibrillation (AF)." | 3.78 | Chloroquine terminates stretch-induced atrial fibrillation more effectively than flecainide in the sheep heart. ( Bandaru, K; Berenfeld, O; Calvo, CJ; Ennis, SR; Filgueiras-Rama, D; Jalife, J; Kalifa, J; Martins, RP; Mironov, S; Noujaim, SF; Yamazaki, M, 2012) |
| "As a molecular model of the effect of ischemia on drug block of the transient outward potassium current, the effect of acidosis on the blocking properties of flecainide and quinidine on Kv4." | 3.72 | Extracellular acidosis modulates drug block of Kv4.3 currents by flecainide and quinidine. ( Bauskin, A; Breit, S; Bursill, J; Campbell, T; Singarayar, S; Vandenberg, J; Wu, W; Wyse, K, 2003) |
| "Antiarrhythmic effects of bisaramil were examined by using new in vivo triggered arrhythmia models, and they were compared with those of other antiarrhythmic drugs." | 3.69 | Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog. ( Haruno, A; Hashimoto, K, 1995) |
| "Electrophysiologic and hemodynamic effects of SD-3212, a new antiarrhythmic drug, were examined and compared with those of flecainide, a class Ic antiarrhythmic drug, in a canine myocardial infarction model." | 3.69 | Comparison of electrophysiologic and hemodynamic effects of SD-3212, a new antiarrhythmic drug, and flecainide in a canine myocardial infarction model. ( Araki, S; Hashimoto, H; Ishii, M; Nagashima, S; Nakashima, M; Uematsu, T; Umemura, K, 1994) |
| "Effects of flecainide, a class I antiarrhythmic drug, on ventricular arrhythmias, ventricular abnormal automaticity and ventricular activation were examined in a canine model of myocardial infarction, and compared with those of lidocaine." | 3.68 | Effects of flecainide on ventricular arrhythmias, abnormal automaticity and activation in a canine model of myocardial infarction. ( Hashimoto, H; Katoh, H; Nakashima, M, 1992) |
| " In these models it is more potent than lidocaine, procainamide and quinidine, as well as a number of investigational agents, and is active against both ventricular and supraventricular arrhythmias from a number of causes." | 3.67 | Antiarrhythmic and electrophysiologic actions of flecainide in animal models. ( Banitt, EH; Kvam, DC; Schmid, JR, 1984) |
| "The properties of a class 1c antiarrhythmic drug, flecainide, were examined using 3 canine ventricular arrhythmia models: (1) digitalis-, (2) adrenaline- and (3) two-stage coronary ligation-induced arrhythmias." | 3.67 | Antiarrhythmic effects of the class 1c antiarrhythmic drug, flecainide, on canine ventricular arrhythmia models. ( Akiyama, K; Hashimoto, K, 1989) |
| "Flecainide has been reported to be effective in suppressing chronic ventricular arrhythmias in clinical studies, but the electrophysiological mechanisms of its action are not understood." | 3.67 | Electrophysiological effects of flecainide in a canine 7 day old myocardial infarction model. ( Hosokawa, M; Miyazaki, T; Nakamura, Y; Ogawa, S; Sakai, T; Sakurai, K, 1989) |
| "Sudden cardiac death from ventricular arrhythmias is more common in adult patients with with heart failure compared with pediatric patients with heart failure." | 1.48 | Acute isoproterenol leads to age-dependent arrhythmogenesis in guinea pigs. ( Chau, S; Miyamoto, SD; Nau, S; Phillips, EK; Stauffer, BL; Sucharov, CC; Tompkins, C; Wilson, CE; Woulfe, KC; Zang, S, 2018) |
| "Fibrosis was triggered by transforming growth factor β (TGF-β) pathway activation." | 1.46 | Transforming growth factor β receptor inhibition prevents ventricular fibrosis in a mouse model of progressive cardiac conduction disease. ( Baró, I; Cerpa, CO; Charpentier, F; Colledge, WH; Derangeon, M; Girardeau, A; Grace, AA; Huang, CLH; Jagu, B; Montnach, J; Patin, J; Toumaniantz, G, 2017) |
| "However, the mechanisms of cardiac arrhythmias in DM1 are unknown." | 1.42 | Abnormal sodium current properties contribute to cardiac electrical and contractile dysfunction in a mouse model of myotonic dystrophy type 1. ( Algalarrondo, V; Azibi, K; Balse, E; Beldjord, C; Coulombe, A; Duboc, D; Eymard, B; Fischmeister, R; Gourdon, G; Hatem, SN; Sebag, F; Wahbi, K, 2015) |
| "Left bundle branch block was induced in 12 canines." | 1.40 | Electrophysiological and haemodynamic effects of vernakalant and flecainide in dyssynchronous canine hearts. ( Auricchio, A; Houthuizen, P; Kuiper, M; Maessen, JG; Prinzen, FW; Strik, M; van Middendorp, LB, 2014) |
| "Flecainide was also potent in suppressing microglial activation in experimental autoimmune encephalomyelitis." | 1.39 | Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. ( Bechtold, D; Chauhdry, S; Hassoon, P; Lee, W; Malpass, K; Morsali, D; Palchaudhuri, U; Piers, T; Pocock, J; Roach, A; Smith, KJ; Snell, DM, 2013) |
| "Control animals developed premature ventricular complexes (PVCs) followed by ventricular tachycardia, which terminated in VF in 5 of the 8 dogs." | 1.39 | HBI-3000 prevents secondary sudden cardiac death. ( Lee, JY; Lucchesi, BR, 2013) |
| "Flecainide is a lipophilic anti-arrhythmic with a significant cardiotoxic profile, with blockade of sodium and potassium channels causing arrhythmias and shock in severe toxicity." | 1.39 | Hypertonic sodium bicarbonate versus intravenous lipid emulsion in a rabbit model of intravenous flecainide toxicity: no difference, no sink. ( Cave, G; Harvey, M; Heys, D; Quinn, P, 2013) |
| "Mutations in pkp2 are detected in arrhythmogenic right ventricular cardiomyopathy (ARVC)." | 1.38 | Sodium current deficit and arrhythmogenesis in a murine model of plakophilin-2 haploinsufficiency. ( Birchmeier, W; Cerrone, M; Chkourko, H; Delmar, M; Hund, T; Liang, FX; Lin, X; Mohler, P; Noorman, M; van der Nagel, R; van Rijen, HV; van Veen, TA, 2012) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by mutations in the cardiac ryanodine receptor (RyR2) or calsequestrin (Casq2) and can be difficult to treat." | 1.37 | Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. ( Faggioni, M; Hasdemir, C; Hwang, HS; Knollmann, BC; Laver, D; Mehra, D; Turhan, K; Yin, H, 2011) |
| "Encainide is a class 1C antiarrhythmic agent that is indicated for the treatment of life-threatening arrhythmias, such as sustained ventricular tachycardia." | 1.28 | Effect of encainide, ODE, MODE, and flecainide on ADP/5-HT induced platelet aggregation and in the anesthetized dog coronary artery stenosis-occlusion model of intravascular thrombosis. ( Antonaccio, MJ; Buchanan, JO; Fleming, JS; Iben, LG; Yocca, FD, 1991) |
| "1." | 1.28 | A dual model for cardiac arrhythmias: coexistence of re-entry and abnormal automaticity and effects of antiarrhythmic agents. ( Hunter, T; Proakis, A; Wu, KM, 1989) |
| " Seven additional postinfarction dogs with noninducible tachycardia during pretreatment programmed stimulation, and thereby considered to be at "low risk" for the development of ischemic ventricular fibrillation, were also given flecainide in an intravenous loading and maintenance dosing regimen." | 1.27 | Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death. ( DiCarlo, L; Kou, WH; Lucchesi, BR; Lynch, JJ; Montgomery, DG; Nelson, SD, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (8.62) | 18.7374 |
| 1990's | 12 (20.69) | 18.2507 |
| 2000's | 10 (17.24) | 29.6817 |
| 2010's | 25 (43.10) | 24.3611 |
| 2020's | 6 (10.34) | 2.80 |
| Authors | Studies |
|---|---|
| Johnson, RE | 1 |
| Baizman, ER | 1 |
| Becker, C | 1 |
| Bohnet, EA | 1 |
| Bell, RH | 1 |
| Birsner, NC | 1 |
| Busacca, CA | 1 |
| Carabateas, PM | 1 |
| Chadwick, CC | 1 |
| Gruett, MD | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Salvage, SC | 1 |
| Habib, ZF | 1 |
| Matthews, HR | 1 |
| Jackson, AP | 1 |
| Huang, CL | 7 |
| Hesselkilde, EZ | 2 |
| Carstensen, H | 2 |
| Flethøj, M | 1 |
| Fenner, M | 1 |
| Kruse, DD | 1 |
| Sattler, SM | 1 |
| Tfelt-Hansen, J | 1 |
| Pehrson, S | 2 |
| Braunstein, TH | 1 |
| Carlson, J | 2 |
| Platonov, PG | 2 |
| Jespersen, T | 3 |
| Buhl, R | 2 |
| Tessarolo Silva, F | 1 |
| Pedreira, GC | 1 |
| Medeiros, SA | 1 |
| Bortolotto, AL | 3 |
| Araujo Silva, B | 1 |
| Hurrey, M | 1 |
| Madhavapeddi, P | 1 |
| Schuler, C | 1 |
| Belardinelli, L | 5 |
| Verrier, RL | 5 |
| Ornelas-Loredo, A | 1 |
| Kany, S | 1 |
| Abraham, V | 1 |
| Alzahrani, Z | 1 |
| Darbar, FA | 1 |
| Sridhar, A | 1 |
| Ahmed, M | 1 |
| Alamar, I | 1 |
| Menon, A | 1 |
| Zhang, M | 1 |
| Chen, Y | 1 |
| Hong, L | 1 |
| Konda, S | 1 |
| Darbar, D | 1 |
| Holmes, AP | 1 |
| Saxena, P | 1 |
| Kabir, SN | 1 |
| O'Shea, C | 1 |
| Kuhlmann, SM | 1 |
| Gupta, S | 1 |
| Fobian, D | 1 |
| Apicella, C | 1 |
| O'Reilly, M | 1 |
| Syeda, F | 1 |
| Reyat, JS | 1 |
| Smith, GL | 1 |
| Workman, AJ | 1 |
| Pavlovic, D | 1 |
| Fabritz, L | 1 |
| Kirchhof, P | 1 |
| Derangeon, M | 1 |
| Montnach, J | 1 |
| Cerpa, CO | 1 |
| Jagu, B | 1 |
| Patin, J | 1 |
| Toumaniantz, G | 1 |
| Girardeau, A | 1 |
| Huang, CLH | 1 |
| Colledge, WH | 3 |
| Grace, AA | 7 |
| Baró, I | 1 |
| Charpentier, F | 1 |
| Haugaard, MM | 1 |
| Hemmeryckx, B | 1 |
| Feng, Y | 1 |
| Frederix, L | 1 |
| Lox, M | 1 |
| Trenson, S | 1 |
| Vreeken, R | 1 |
| Lu, HR | 1 |
| Gallacher, D | 1 |
| Ni, Y | 1 |
| Lijnen, HR | 1 |
| Silva, BA | 2 |
| Marum, AA | 2 |
| Stocco, FG | 1 |
| Evaristo, E | 1 |
| de Antonio, VZ | 2 |
| Silva, AC | 2 |
| Woulfe, KC | 1 |
| Wilson, CE | 1 |
| Nau, S | 1 |
| Chau, S | 1 |
| Phillips, EK | 1 |
| Zang, S | 1 |
| Tompkins, C | 1 |
| Sucharov, CC | 1 |
| Miyamoto, SD | 1 |
| Stauffer, BL | 1 |
| Morsali, D | 1 |
| Bechtold, D | 1 |
| Lee, W | 1 |
| Chauhdry, S | 1 |
| Palchaudhuri, U | 1 |
| Hassoon, P | 1 |
| Snell, DM | 1 |
| Malpass, K | 1 |
| Piers, T | 1 |
| Pocock, J | 1 |
| Roach, A | 1 |
| Smith, KJ | 1 |
| Lee, JY | 1 |
| Lucchesi, BR | 2 |
| Cave, G | 1 |
| Harvey, M | 1 |
| Quinn, P | 1 |
| Heys, D | 1 |
| van Middendorp, LB | 1 |
| Strik, M | 1 |
| Houthuizen, P | 1 |
| Kuiper, M | 1 |
| Maessen, JG | 1 |
| Auricchio, A | 1 |
| Prinzen, FW | 1 |
| Desaphy, JF | 1 |
| Carbonara, R | 1 |
| Costanza, T | 1 |
| Conte Camerino, D | 1 |
| Kirchhoff, JE | 1 |
| Diness, JG | 1 |
| Sheykhzade, M | 1 |
| Grunnet, M | 1 |
| Algalarrondo, V | 1 |
| Wahbi, K | 1 |
| Sebag, F | 1 |
| Gourdon, G | 1 |
| Beldjord, C | 1 |
| Azibi, K | 1 |
| Balse, E | 1 |
| Coulombe, A | 1 |
| Fischmeister, R | 1 |
| Eymard, B | 1 |
| Duboc, D | 1 |
| Hatem, SN | 1 |
| Osadchii, OE | 1 |
| Duchêne, A | 1 |
| Perier, M | 1 |
| Zhao, Y | 1 |
| Liu, X | 1 |
| Thomasson, J | 1 |
| Chauveau, F | 1 |
| Piérard, C | 1 |
| Lagarde, D | 1 |
| Picoli, C | 1 |
| Jeanson, T | 1 |
| Mouthon, F | 1 |
| Dauvilliers, Y | 1 |
| Giaume, C | 1 |
| Lin, JS | 1 |
| Charvériat, M | 1 |
| Bacic, D | 1 |
| Carneiro, JS | 1 |
| Bento, AA | 1 |
| Nearing, BD | 1 |
| Rajamani, S | 1 |
| Dautova, Y | 2 |
| Zhang, Y | 2 |
| Sabir, I | 1 |
| Hwang, HS | 1 |
| Hasdemir, C | 1 |
| Laver, D | 1 |
| Mehra, D | 1 |
| Turhan, K | 1 |
| Faggioni, M | 1 |
| Yin, H | 1 |
| Knollmann, BC | 1 |
| Allison, B | 1 |
| Yang, Y | 1 |
| Pourrier, M | 1 |
| Gibson, JK | 1 |
| Martin, CA | 1 |
| Guzadhur, L | 1 |
| Lei, M | 1 |
| Liu, N | 2 |
| Denegri, M | 1 |
| Ruan, Y | 1 |
| Avelino-Cruz, JE | 1 |
| Perissi, A | 1 |
| Negri, S | 1 |
| Napolitano, C | 2 |
| Coetzee, WA | 1 |
| Boyden, PA | 1 |
| Priori, SG | 2 |
| Filgueiras-Rama, D | 1 |
| Martins, RP | 1 |
| Mironov, S | 1 |
| Yamazaki, M | 1 |
| Calvo, CJ | 1 |
| Ennis, SR | 1 |
| Bandaru, K | 1 |
| Noujaim, SF | 1 |
| Kalifa, J | 1 |
| Berenfeld, O | 1 |
| Jalife, J | 1 |
| Cerrone, M | 1 |
| Noorman, M | 1 |
| Lin, X | 1 |
| Chkourko, H | 1 |
| Liang, FX | 1 |
| van der Nagel, R | 1 |
| Hund, T | 1 |
| Birchmeier, W | 1 |
| Mohler, P | 1 |
| van Veen, TA | 1 |
| van Rijen, HV | 1 |
| Delmar, M | 1 |
| Venetucci, LA | 1 |
| Singarayar, S | 1 |
| Bursill, J | 1 |
| Wyse, K | 1 |
| Bauskin, A | 1 |
| Wu, W | 1 |
| Vandenberg, J | 1 |
| Breit, S | 1 |
| Campbell, T | 1 |
| Stokoe, KS | 2 |
| Thomas, G | 1 |
| Goddard, CA | 3 |
| Balasubramaniam, R | 1 |
| Milberg, P | 1 |
| Tegelkamp, R | 1 |
| Osada, N | 1 |
| Schimpf, R | 1 |
| Wolpert, C | 1 |
| Breithardt, G | 1 |
| Borggrefe, M | 1 |
| Eckardt, L | 1 |
| Kaufman, ES | 1 |
| Sabir, IN | 1 |
| Li, LM | 1 |
| Jones, VJ | 1 |
| Tamargo Menéndez, J | 1 |
| Kvam, DC | 1 |
| Banitt, EH | 1 |
| Schmid, JR | 1 |
| Haruno, A | 1 |
| Hashimoto, K | 2 |
| Salerno, DM | 1 |
| Murakami, MM | 1 |
| Johnston, RB | 1 |
| Keyler, DE | 1 |
| Pentel, PR | 1 |
| Hashimoto, H | 2 |
| Umemura, K | 1 |
| Araki, S | 1 |
| Ishii, M | 1 |
| Nagashima, S | 1 |
| Uematsu, T | 1 |
| Nakashima, M | 2 |
| Ogawa, S | 2 |
| Mitamura, H | 1 |
| Katoh, H | 2 |
| Aupetit, JF | 2 |
| Timour, Q | 2 |
| Larbre, JP | 2 |
| Loufoua-Moundanga, J | 2 |
| Kioueh, I | 1 |
| Lopez, M | 1 |
| Faucon, G | 2 |
| Gout, B | 1 |
| Nichols, AJ | 1 |
| Feuerstein, GZ | 1 |
| Bril, A | 1 |
| Hallman, K | 1 |
| Carlsson, L | 1 |
| Wijffels, MC | 1 |
| Dorland, R | 1 |
| Allessie, MA | 2 |
| Danse, PW | 1 |
| Garratt, CJ | 1 |
| Mast, F | 1 |
| Ichimata, M | 1 |
| Kitano, T | 1 |
| Ikebe, H | 1 |
| Iwasaka, H | 1 |
| Noguchi, T | 1 |
| Gerentes-Chassagne, I | 1 |
| Fleming, JS | 1 |
| Buchanan, JO | 1 |
| Yocca, FD | 1 |
| Iben, LG | 1 |
| Antonaccio, MJ | 1 |
| Wu, KM | 1 |
| Hunter, T | 1 |
| Proakis, A | 1 |
| Akiyama, K | 1 |
| Sakai, T | 1 |
| Hosokawa, M | 1 |
| Miyazaki, T | 1 |
| Sakurai, K | 1 |
| Nakamura, Y | 1 |
| Kou, WH | 1 |
| Nelson, SD | 1 |
| Lynch, JJ | 1 |
| Montgomery, DG | 1 |
| DiCarlo, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Therapeutic Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation in Healthy Subjects[NCT03182413] | Phase 1 | 20 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study[NCT02932007] | Phase 2 | 40 participants (Anticipated) | Interventional | 2017-03-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for flecainide and Disease Models, Animal
| Article | Year |
|---|---|
Ca2+-dependent modulation of voltage-gated myocyte sodium channels.
Topics: Action Potentials; Animals; Binding Sites; Calcium; Calcium Signaling; Disease Models, Animal; Fleca | 2021 |
Pulmonary Delivery of Antiarrhythmic Drugs for Rapid Conversion of New-Onset Atrial Fibrillation.
Topics: Administration, Inhalation; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, An | 2020 |
Flecainide and antiarrhythmic effects in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
Topics: Animals; Anti-Arrhythmia Agents; Catecholamines; Disease Models, Animal; Flecainide; Mice; Myocytes, | 2012 |
Quinidine in short QT syndrome: an old drug for a new disease.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; | 2007 |
[New strategies in the treatment of atrial fibrillation].
Topics: Action Potentials; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anim | 2007 |
53 other studies available for flecainide and Disease Models, Animal
| Article | Year |
|---|---|
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzodiazepines; Cats; Disease Models, Animal | 1993 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Longitudinal study of electrical, functional and structural remodelling in an equine model of atrial fibrillation.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function, Left; Atri | 2019 |
Multimodal mechanisms and enhanced efficiency of atrial fibrillation cardioversion by pulmonary delivery of a novel flecainide formulation.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Action Potentials; Administration, Inhalation; Animals; Anti-Arrh | 2020 |
Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs.
Topics: Aged; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Diet, High-Fat; Disease Models, Animal; | 2020 |
Atrial resting membrane potential confers sodium current sensitivity to propafenone, flecainide and dronedarone.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dro | 2021 |
Transforming growth factor β receptor inhibition prevents ventricular fibrosis in a mouse model of progressive cardiac conduction disease.
Topics: Age Factors; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzamides; Cardiomyopathies; Co | 2017 |
Effect of flecainide on atrial fibrillatory rate in a large animal model with induced atrial fibrillation.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; | 2017 |
Evaluation of cardiac arrhythmic risks using a rabbit model of left ventricular systolic dysfunction.
Topics: Animals; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; Flecainide; Magnetic Res | 2018 |
Accelerated conversion of atrial fibrillation to normal sinus rhythm by pulmonary delivery of flecainide acetate in a porcine model.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dose-Response Relation | 2018 |
Acute isoproterenol leads to age-dependent arrhythmogenesis in guinea pigs.
Topics: Action Potentials; Age Factors; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden | 2018 |
Optimizing flecainide plasma concentration profile for atrial fibrillation conversion while minimizing adverse ventricular effects by rapid, low-dose intratracheal or intravenous administration.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Disease Models, Animal; Dose-Respo | 2019 |
Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.
Topics: Alanine; Animals; Benzylamines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; | 2013 |
HBI-3000 prevents secondary sudden cardiac death.
Topics: Animals; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Disease Models, Animal; Dogs; Dose-Response | 2013 |
Hypertonic sodium bicarbonate versus intravenous lipid emulsion in a rabbit model of intravenous flecainide toxicity: no difference, no sink.
Topics: Animals; Anti-Arrhythmia Agents; Antidotes; Blood Pressure; Disease Models, Animal; Endpoint Determi | 2013 |
Electrophysiological and haemodynamic effects of vernakalant and flecainide in dyssynchronous canine hearts.
Topics: Action Potentials; Animals; Anisoles; Anti-Arrhythmia Agents; Blood Pressure; Bundle-Branch Block; C | 2014 |
Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.
Topics: Animals; Carbamazepine; Disease Models, Animal; Flecainide; HEK293 Cells; Humans; Mexiletine; Muscle | 2014 |
Synergistic antiarrhythmic effect of combining inhibition of Ca²⁺-activated K⁺ (SK) channels and voltage-gated Na⁺ channels in an isolated heart model of atrial fibrillation.
Topics: Acetanilides; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Drug Syn | 2015 |
Abnormal sodium current properties contribute to cardiac electrical and contractile dysfunction in a mouse model of myotonic dystrophy type 1.
Topics: Action Potentials; Aging; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; C | 2015 |
Flecainide attenuates rate adaptation of ventricular repolarization in guinea-pig heart.
Topics: Action Potentials; Adaptation, Physiological; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; | 2016 |
Impact of Astroglial Connexins on Modafinil Pharmacological Properties.
Topics: Animals; Astrocytes; Benzhydryl Compounds; Connexin 30; Connexin 43; Connexins; Disease Models, Anim | 2016 |
Eleclazine, an inhibitor of the cardiac late sodium current, is superior to flecainide in suppressing catecholamine-induced ventricular tachycardia and T-wave alternans in an intact porcine model.
Topics: Administration, Intravenous; Animals; Catecholamines; Disease Models, Animal; Drug Monitoring; Elect | 2017 |
Atrial arrhythmogenesis in wild-type and Scn5a+/delta murine hearts modelling LQT3 syndrome.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Flecainide; Heart Rate | 2009 |
Atrial arrhythmogenic properties in wild-type and Scn5a+/- murine hearts.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Function; Brugada Syndrome; Cardiac Pacin | 2010 |
Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Calsequestrin; Defi | 2011 |
Comparison of the in vivo hemodynamic effects of the antiarrhythmic agents vernakalant and flecainide in a rat hindlimb perfusion model.
Topics: Animals; Anisoles; Anti-Arrhythmia Agents; Aorta, Abdominal; Blood Pressure; Disease Models, Animal; | 2011 |
Mapping of reentrant spontaneous polymorphic ventricular tachycardia in a Scn5a+/- mouse model.
Topics: Animals; Anti-Arrhythmia Agents; Brugada Syndrome; Disease Models, Animal; Electrocardiography; Elec | 2011 |
Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.
Topics: Animals; Anti-Arrhythmia Agents; Calcium Signaling; Disease Models, Animal; Extracellular Space; Fle | 2011 |
Chloroquine terminates stretch-induced atrial fibrillation more effectively than flecainide in the sheep heart.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antirheumatic Agents; Atrial Fibrillation; Chlor | 2012 |
Sodium current deficit and arrhythmogenesis in a murine model of plakophilin-2 haploinsufficiency.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Dise | 2012 |
Extracellular acidosis modulates drug block of Kv4.3 currents by flecainide and quinidine.
Topics: Acidosis; Animals; Anti-Arrhythmia Agents; Biological Transport, Active; Cricetinae; Cricetulus; Dis | 2003 |
Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Delta murine hearts modelling long QT syndrome 3.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electric Stimulation; El | 2007 |
Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/- murine hearts modelling the Brugada syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Brugada Syndrome; Disease Models, Animal; Electr | 2007 |
Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Do | 2007 |
Criteria for arrhythmogenicity in genetically-modified Langendorff-perfused murine hearts modelling the congenital long QT syndrome type 3 and the Brugada syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Brugada Syndrome; Cardiac Pacing, Artificial; Di | 2008 |
Antiarrhythmic and electrophysiologic actions of flecainide in animal models.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Do | 1984 |
Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bridged Bicyclo Compounds, Heterocyclic; Chlo | 1995 |
Reversal of flecainide-induced ventricular arrhythmia by hypertonic sodium bicarbonate in dogs.
Topics: Animals; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Electrocardiography; Flecainide; | 1995 |
Comparison of electrophysiologic and hemodynamic effects of SD-3212, a new antiarrhythmic drug, and flecainide in a canine myocardial infarction model.
Topics: Animals; Anti-Arrhythmia Agents; Blood Pressure; Cardiac Output; Disease Models, Animal; Dogs; Dose- | 1994 |
Effect of E-4031, a new class III antiarrhythmic drug, on reentrant ventricular arrhythmias: comparison with conventional class I drugs.
Topics: Animals; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disease Models, Animal; Disopyrami | 1993 |
Arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders: possible aggravation by myocardial ischemia--study in the porcine in situ heart.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; | 1993 |
Antifibrillatory effects of BRL-32872 in anesthetized Yucatan minipigs with regional myocardial ischemia.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Benzamides; Disease Models, Animal; Flecainid | 1995 |
Prevention of class III-induced proarrhythmias by flecainide in an animal model of the acquired long QT syndrome.
Topics: Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Disease Models, | 1995 |
Pharmacologic cardioversion of chronic atrial fibrillation in the goat by class IA, IC, and III drugs: a comparison between hydroquinidine, cibenzoline, flecainide, and d-sotalol.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Disease Models, Animal; Elect | 1999 |
Preferential depression of conduction around a pivot point in rabbit ventricular myocardium by potassium and flecainide.
Topics: Animals; Anti-Arrhythmia Agents; Body Surface Potential Mapping; Cardiac Pacing, Artificial; Cathete | 2000 |
Flecainide reverses neuropathic pain and suppresses ectopic nerve discharge in rats.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dose-Response Relationsh | 2001 |
Effects of flecainide on ventricular arrhythmias, abnormal automaticity and activation in a canine model of myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Electrocardiography; Flecainide; Heart | 1992 |
[Arrhythmogenic risk of antiarrhythmic drugs: study with class Ic drugs during myocardial ischemia].
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Coronary Disease; | 1991 |
Effect of encainide, ODE, MODE, and flecainide on ADP/5-HT induced platelet aggregation and in the anesthetized dog coronary artery stenosis-occlusion model of intravascular thrombosis.
Topics: Adenosine Diphosphate; Anilides; Animals; Anti-Arrhythmia Agents; Coronary Circulation; Coronary Thr | 1991 |
A dual model for cardiac arrhythmias: coexistence of re-entry and abnormal automaticity and effects of antiarrhythmic agents.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Female; Flecain | 1989 |
Antiarrhythmic effects of the class 1c antiarrhythmic drug, flecainide, on canine ventricular arrhythmia models.
Topics: Animals; Arrhythmias, Cardiac; Coronary Vessels; Disease Models, Animal; Dogs; Epinephrine; Flecaini | 1989 |
Electrophysiological effects of flecainide in a canine 7 day old myocardial infarction model.
Topics: Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Electrocard | 1989 |
Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death.
Topics: Animals; Death, Sudden; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Electric Stimula | 1987 |